Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia

Leukemia

Volumn 23, Issue 11, 2009, Pages 2018-2026

  Farfsing, A ^a   Engel, F ^a   Seiffert, M ^a   Hartmann, E ^b   Ott, G ^b,e   Rosenwald, A ^b   Stilgenbauer, S ^c   Dohner H ^c   Boutros, M ^d   Lichter, P ^a   Pscherer, A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COILED COIL DOMAIN CONTAINING PROTEIN 50; GENE PRODUCT; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; P21 ACTIVATED KINASE 2; PROTEIN ACTL6A; PROTEIN APOD; PROTEIN BCHE; PROTEIN DVL3; PROTEIN ECE2; PROTEIN ECT2; PROTEIN ETV5; PROTEIN FAM43A; PROTEIN GPR160; PROTEIN KLHL6; PROTEIN LAMP3; PROTEIN LEPREL1; PROTEIN LRCH3; PROTEIN PFN2; PROTEIN RARRES1; PROTEIN RFC4; PROTEIN RPL39L; PROTEIN SERPINI2; PROTEIN SMARCC2; PROTEIN SMC4; PROTEIN USP13; PROTEIN YEATS2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME 12Q; CHROMOSOME 18Q; CHROMOSOME 3Q; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ANALYSIS; GENETIC IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

BONE MARROW CELLS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENOMICS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, MANTLE-CELL; NEOPLASM PROTEINS; NF-KAPPA B; PROTEIN STRUCTURE, TERTIARY; RNA, SMALL INTERFERING; SERPINS; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 70450267531     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.144     Document Type: Article

References (57)

1. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115-127. unbedingt noch neuere Referenzen dazu.
2. Erikson J, Finan J, Tsujimoto Y, Nowell PC, Croce CM. The chromosome 14 breakpoint in neoplastic B cells with the t(11;14) translocation involves the immunoglobulin heavy chain locus. Proc Natl Acad Sci USA 1984; 81: 4144-4148.
3. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099.
4. Bentz M, Plesch A, Bullinger L, Stilgenbauer S, Ott G, Muller-Hermelink HK et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer 2000; 27: 285-294.
5. Schaffner C, Idler I, Stilgenbauer S, Dohner H, Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc Natl Acad Sci USA 2000; 97: 2773-2778.
6. Solinas-Toldo S, Durst M, Lichter P. Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. Proc Natl Acad Sci USA 1997; 94: 3854-3859.
7. Monni O, Oinonen R, Elonen E, Franssila K, Teerenhovi L, Joensuu H et al. Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma. Genes Chromosomes Cancer 1998; 21: 298-307.
8. de Leeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ et al. Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. Hum Mol Genet 2004; 13: 1827-1837.
9. Kohlhammer H, Schwaenen C, Wessendorf S, Holzmann K, Kestler HA, Kienle D et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004; 1 104 (3): 795-801.
10. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A et al. Genome-wide array-based CGH for mantle cell lymphoma: Identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348-1358.
11. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105: 4445-4454.
12. Schraders M, Pfundt R, Straatman HM, Janssen IM, van Kessel AG, Schoenmakers EF et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 2005; 105: 1686-1693.
13. Schraders M, Jares P, Bea S, Schoenmakers EF, van Krieken JH, Campo E et al. Integrated genomic and expression profiling in mantle cell lymphoma: Identification of gene-dosage regulated candidate genes. Br J Haematol 2008; 143: 210-221.
14. Sander S, Bullinger L, Leupolt E, Benner A, Kienle D, Katzenberger T et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica 2008; 93: 680-687.
15. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98: 787-794.
16. Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 2002; 119: 905-915.
17. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-8232.
18. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197.
19. de Vos S, Krug U, Hofmann WK, Pinkus GS, Swerdlow SH, Wachsman W et al. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 2003; 12: 35-43.
20. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2007; 109: 271-280.
21. Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signaling pathways. Br J Haematol 2005; 130: 516-526.
22. Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007; 25: 1216-1222.
23. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937-3949.
24. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. Leuk Lymphoma 2008; 49: 864-873.
25. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142: 149-165.
26. Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L et al Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93: 4365-4374.
27. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
28. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
29. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115 755-764.
30. Dighiero G, Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: Present status and future directions. French Cooperative Group on CLL. Blood 1991; 78: 1901-1914.
31. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
32. Seiffert M, Stilgenbauer S, Dohner H, Lichter P. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids. Leukemia 2007; 21: 1977-1983.
33. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003; 4: 609-615.
34. Pscherer A, Schliwka J, Wildenberger K, Mincheva A, Schwaenen C, Dohner H et al. Antagonizing inactivated tumor suppressor genes and activated oncogenes by a versatile transgenesis system: Application in mantle cell lymphoma. FASEB J 2006; 20: 1188-1190.
35. Korz C, Pscherer A, Benner A, Mertens D, Schaffner C, Leupolt E et al Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 2002; 99: 4554-4561.
36. Kameda H, Watanabe M, Bohgaki M, Tsukiyama T, Hatakeyama S. Inhibition of NF-kappaB signaling via tyrosine phosphorylation of Ymer. Biochem Biophys Res Commun 2009; 378: 744-749.
37. Bohgaki M, Tsukiyama T, Nakajima A, Maruyama S, Watanabe M, Koike T et al. Involvement of Ymer in suppression of NF-kappaB activation by regulated interaction with lysine-63-linked polyubiquitin chain. Biochim Biophys Acta 2008; 1783: 826-837.
38. Schmechel SC, LeVasseur RJ, Yang KH, Koehler KM, Kussick SJ, Sabath DE. Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. Leukemia 2004; 18: 841-855.
39. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol 2006; 24: 22-27.
40. Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006; 103: 2352-2357.
41. Falt S, Merup M, Gahrton G, Lambert B, Wennborg A. Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol 2005; 33: 883-893.
42. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
43. Snove Jr O, Nedland M, Fjeldstad SH, Humberset H, Birkeland OR, Grunfeld T et al. Designing effective siRNAs with off-target control. Biochem Biophys Res Commun 2004; 325: 769-773.
44. Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A et al. Off-target effects of siRNA specific for GFP. BMC Mol Biol 2008; 9: 60.
45. Tashiro K, Konishi H, Sano E, Nabeshi H, Yamauchi E, Taniguchi H. Suppression of the ligand-mediated down-regulation of epidermal growth factor receptor by Ymer, a novel tyrosine-phosphorylated and ubiquitinated protein. J Biol Chem 2006; 281: 24612-24622.
46. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 2000; 60: 1143-1151.
47. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Biol Chem 1996; 271: 18068-18073.
48. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
49. Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 2002; 30: 315-320.
50. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994; 266: 1376-1380.
51. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. Direct activation of Bax by p53 mediates mtochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.
52. Kerley-Hamilton JS, Pike AM, Li N, DiRenzo J, Spinella MJ. A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma. Oncogene 2005; 24 6090-6100.
53. Adamsen BL, Kravik KL, Clausen OP, De Angelis PM. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 2007; 31: 1491-1500.
54. Phang JM, Donald SP, Pandhare J, Liu Y. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids 2008; 35: 681-690.
55. Pulverer B, Sommer A, McArthur GA, Eisenman RN, Luscher B. Analysis of Myc/Max/Mad network members in adipogenesis: Inhibition of the proliferative burst and differentiation by ectopically expressed Mad1. J Cell Physiol 2000; 183: 399-410.
56. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: Cancer implications. Nat Rev Cancer 2009; 9: 95-107.
57. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, Heuberger M et al. Treatment resistance in chronic lymphocytic leukemia: The role of the p53 pathway. Leuk Lymphoma 2009; 50: 510-513.